CNTX Context Therapeutics Inc.

NASDAQ
$0.17

Context Therapeutics Inc. (CNTX) is expected to report earnings on February 9, 2027, after the market close. The consensus earnings estimate is a loss of $0.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.8% since its last earnings release on November 10, 2026.

Context Therapeutics Beat Consensus Estimates
Tuesday, November 10, 2026 · 4:16 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 9
Tuesday · 4:15 PM ET
Earnings Whisper
-
vs ($0.08)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.18

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Context Therapeutics Inc.

Context Therapeutics Inc. is a biopharmaceutical company committed to advancing medicines for solid tumors.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.